Evaluation of Blood Protein O-GlcNAcylation Levels in Children
Recruiting now
Conditions studied: Sepsis, Septic Shock, Development and Health, Metabolism Changes
In brief
Stimulation of O-GlcNAcylation has been shown to be beneficial in several acute pathologies and different animal models, such as haemorrhagic and septic shock, and ischaemia-reperfusion (cerebral and cardiac). It could therefore be interesting to use this approach in children in order to limit the impact of various pathologies inducing SIRS, such as extracorporeal circulation for major surgery, septic shock or various traumas. The investigators demonstrated in 2 different animal models (endotoxemia by injection of Lipopolysaccharides and caecal puncture ligation model) with 3 different pharmacological molecules (Glucosamine, ThiametG and NButGT) that stimulation of O-GlcNAcylation was beneficial in the early phase of septic shock with a marked effect on cardiac function and survival. The investigators thus demonstrated that stimulation of O-GlcNAcylation was beneficial in young rats in septic shock. However, none of this work has yet been reproduced in humans, either children or adults.
Key facts
- Study ID
- NCT06754696
- Run by
- Nantes University Hospital
- People needed
- 240
- Starts
- 2025-01-30
- Expected to finish
- 2036-01-31
- Last updated by the study team
- 2025-02-13
Who can join
Age: any, up to 17. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age from 0 to 17 years at the time of sampling (including premature infants)
- Children coming to hospital for a blood sample to be taken as part of a pre-operative check-up, an allergy check-up or a check-up as part of a pathology other than sepsis.
- Premature infants benefiting from a blood sample as part of their monitoring and management of prematurity
- Collection of umbilical cord blood
- Signed consent
You may not qualify if…
- Children with an infection
- Children with fever
- Children with an immune deficiency
- Children with autoimmune disease
- Children with metabolic disease
- Children with haematological diseases
- Children with a genetic disease
- Unsigned consent
- Refusal by parents or child
- Septic group
- Inclusion Criteria :
- Age from 0 to 17 years at the time of sampling (including preterm infants)
- Children with suspected sepsis or diagnosed sepsis according to the 2016 definition
- Premature infants having blood drawn for suspected or diagnosed sepsis
- All responsible bacteria, viruses or fungi
- Signed bio-collection consent
- Exclusion Criteria :
- Children with an immune deficiency
- Children with autoimmune disease
- Children with a metabolic disease
- Children with haematological diseases
- Children with a genetic disease
- Unsigned bio-collection consent
- Refusal by parents or child
Where it is running
- Nantes University Hospital — Nantes, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.